Major ArticleOral rifampin for eradication of Staphylococcus aureus carriage from healthy and sick populations: A systematic review of the evidence from comparative trials
Section snippets
Searching
PubMed (January 1950 until March 2006) and the Cochrane Central Register of Controlled Trials were the databases in which we searched for relevant studies. Also, the references from relevant studies and review papers were checked. Search terms included: rifampin, rifampicin, Staphylococcus aureus, colonization, colonisation, carriage, randomized controlled trial, trial, and combinations of these terms. In addition, the search filter proposed by the Cochrane database for the identification of
Trial flow
Our literature search identified 39 potentially relevant clinical studies.12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50 Fig 1 is a flow diagram showing the steps we followed to identify the studies fulfilling the inclusion criteria of our review. As shown, 9 comparative trials were finally considered eligible for inclusion.19, 32, 33, 36, 40, 42, 46, 47, 48 Six of the analyzed studies
Discussion
Our analysis regarding the effectiveness and safety of rifampin when used to reduce the carriage of S. aureus in various populations revealed two main points. First, when comparing rifampin regimens with no treatment, it was shown that the antibiotic is effective in the eradication of S. aureus carriage.30, 31, 44 Second, an overview of the 4 studies that compared rifampin monotherapy or rifampin-based regimens with other antibiotics for the eradication of S. aureus carriage suggests that
References (61)
- et al.
The role of nasal carriage in Staphylococcus aureus infections
Lancet Infect Dis
(2005) - et al.
Thrombocytopenia—a rare but potentially serious side effect of initial daily and interrupted use of rifampicin
Chest
(1989) - et al.
Acute renal failure after rifampicin
Lancet
(1972) - et al.
A randomized trial of Staphylococcus aureus prophylaxis in peritoneal dialysis patients: mupirocin calcium ointment 2% applied to the exit site versus cyclic oral rifampin
Am J Kidney Dis
(1996) - et al.
Antibiotic-coated hemodialysis catheters for the prevention of vascular catheter-related infections: a prospective, randomized study
Am J Med
(2003) - et al.
Prophylaxis of graft infection with rifampin-bonded Gelseal graft: 2-year follow-up of a prospective clinical trial. Italian Investigators Group
Cardiovasc Surg
(1996) - et al.
Evaluation of in vitro activity of quinupristin/dalfopristin and comparator antimicrobial agents against worldwide clinical trial and other laboratory isolates
Am J Med
(1998) - et al.
Factors associated with cure after therapy of clinical mastitis caused by Staphylococcus aureus
J Dairy Sci
(2000) - et al.
Randomized controlled trial of prophylactic rifampin for peritoneal dialysis-related infections
Am J Kidney Dis
(1991) - et al.
Resistance development in community-acquired strains of methicillin-resistant Staphylococcus aureus: an in vitro study
Int J of Antimicrob Agents
(2004)
The importance of the development of antibiotic resistance in Staphylococcus aureus
Clin Microbiol Infect
World-wide antibiotic resistance in meticillin-resistant Staphylococcus aureus
Lancet
Mupirocin resistance in coagulase-negative staphylococci, after topical prophylaxis for the reduction of colonization of central venous catheters
J Hosp Infect
Nasal carriage of Staphylococcus aureus: epidemiology, underlying mechanisms and associated risks
Clin Microbiol Rev
Staphylococcal nasal carriage and subsequent infection in peritoneal dialysis patients
JAMA
Risk factors for hospital-acquired Staphylococcus aureus bacteremia
Arch Intern Med
Methicillin-resistant Staphylococcus aureus (MRSA) nares colonization at hospital admission and its effect on subsequent MRSA infection
Clin Infect Dis
European best practice guidelines for peritoneal dialysis. 3 peritoneal access
Nephrol Dial Transplant
Bacterial interference among strains of Staphylococcus aureus in man
J Infect Dis
Adverse effects of rifampin
Rev Infect Dis
Alteration of staphylococcal flora in cardiac surgery patients receiving antibiotic prophylaxis
J Infect Dis
The treatment of Staphylococcus aureus nasal carriage in pediatric peritoneal dialysis patients
Adv Perit Dial
Etiology and therapy of chronic suppurative otitis
J Chemother
Multiple-dose pharmacokinetics of concurrent oral ciprofloxacin and rifampin therapy in elderly patients
Antimicrob Agents Chemother
Eradication of colonization by methicillin-resistant Staphylococcus aureus by using oral minocycline-rifampin and topical mupirocin
Antimicrob Agents Chemother
Intraperitoneal ciprofloxacin and rifampicin versus cephradine as initial treatment of (C) APD-related peritonitis: a prospective randomized multicenter comparison (CIPPER trial)
Perit Dial Int
Oral rifampin plus ofloxacin for treatment of Staphylococcus-infected orthopedic implants
Antimicrob Agents Chemother
Steady-state serum pharmacokinetics of novobiocin and rifampin alone and in combination
Antimicrob Agents Chemother
Continuous ambulatory peritoneal dialysis catheter infections: diagnosis and management
Perit Dial Int
Cited by (71)
Investigation on rifampicin administration from the standpoint of pharmacokinetics/pharmacodynamics in a neutropenic murine thigh infection model
2016, Journal of Infection and ChemotherapyCitation Excerpt :Biofilm formation of S. aureus isolates facilitates patient mortality and promotes the probability of the development of antimicrobial resistance [16]. Although statistically significantly higher cure rates with rifampicin treatment have been observed in only a few studies [10,11,17,18], rifampicin has been used because of its good activity against Staphylococcus spp. [4–6,19]. In one systematic review, adjunctive rifampicin with β-lactam or glycopeptide monotherapy in S. aureus bacteremia was associated with the reduction of all-cause mortality and clinical or bacteriological failure [20].
Prevention of Recurrent Staphylococcal Skin Infections
2015, Infectious Disease Clinics of North AmericaAntibiotic Treatment of Resistant Infections in Small Animals
2013, Veterinary Clinics of North America - Small Animal PracticeCitation Excerpt :Resistance occurs through mutations and clonal spread of a resistant strain. To reduce the rate of mutation, combination therapy with other agents has usually been recommended in human guidelines,53 as was the recommendation from a veterinary study.51 However, experimental infections caused by Staphylococcus have been successfully treated with rifampin monotherapy.54